Clinical drug interaction profile of idelalisib in healthy subjects
Author:
Affiliation:
1. Gilead Sciences, Inc.; Foster City CA USA
2. Gilead Sciences, Inc.; Seattle WA USA
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.495/fullpdf
Reference23 articles.
1. PI3K in lymphocyte development, differentiation and activation;Okkenhaug;Nat Rev Immunol,2003
2. Signalling by PI3K isoforms: insights from gene-targeted mice;Vanhaesebroeck;Trends Biochem Sci,2005
3. The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia;Herman;Blood,2011
4. Survival of leukemic B cells promoted by engagement of the antigen receptor;Bernal;Blood,2001
5. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability;Lannutti;Blood,2011
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. TBA(FeCl3Br) Complex as a Photocatalyst in the Csp3–H Bond Activation in Alcohols for the Synthesis of N-Based Heterocycles;ACS Sustainable Chemistry & Engineering;2024-06-25
2. Challenges and Opportunities for In Vitro–In Vivo Extrapolation of Aldehyde Oxidase-Mediated Clearance: Toward a Roadmap for Quantitative Translation;Drug Metabolism and Disposition;2023-09-26
3. Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia;Expert Opinion on Drug Metabolism & Toxicology;2023-09-02
4. Advances in the Discovery of Novel Inhaled PI3Kδ Inhibitors for the Treatment of Asthma;Current Medicinal Chemistry;2023-05
5. IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance;Cancer Research Communications;2023-04-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3